---
title: "A-share subscription | FENGBEI BIOTECH starts subscription with existing biodiesel production capacity of 105,000 tons"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262786292.md"
description: "FENGBEI BIOTECH started its subscription on October 27, with an issue price of 24.49 yuan per share, a subscription limit of 11,000 shares, and a price-to-earnings ratio of 30.47 times. The company focuses on the comprehensive utilization of waste oil resources, with an existing biodiesel production capacity of 105,000 tons, ranking sixth in the industry. From 2022 to 2024, the company's operating revenues are projected to be 1.709 billion yuan, 1.728 billion yuan, and 1.948 billion yuan, with net profits of 133 million yuan, 130 million yuan, and 124 million yuan, respectively. The net cash flow from operating activities is expected to decline in 2024"
datetime: "2025-10-26T22:38:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262786292.md)
  - [en](https://longbridge.com/en/news/262786292.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262786292.md)
---

# A-share subscription | FENGBEI BIOTECH starts subscription with existing biodiesel production capacity of 105,000 tons

According to Zhitong Finance APP, on October 27, FENGBEI BIOTECH (603334.SH) opened for subscription, with an issue price of 24.49 yuan per share and a subscription limit of 11,000 shares. It is listed on the Shanghai Stock Exchange, with a price-to-earnings ratio of 30.47 times, and Guotai Junan Securities is its sponsor.

The prospectus reveals that FENGBEI BIOTECH is a high-tech enterprise in the field of comprehensive utilization of waste resources, mainly producing resource-based products from waste oils, forming a waste resource recycling industry chain of "waste oils—biofuels (biodiesel)—biobased materials." The company's main business focuses on the comprehensive utilization of waste oil resources, supplemented by the oil chemical products business. The main products of the comprehensive utilization of waste oil resources are biobased materials and biofuels, where biobased materials mainly include pesticide additives, fertilizer additives, and industrial-grade mixed oils; biofuels mainly consist of biodiesel; the main products of the oil chemical products business include DD oil and fatty acids.

FENGBEI BIOTECH has established long-term cooperation with many leading enterprises in the agricultural chemical field, such as Fengle Seed Industry, Jiuyi Co., Ltd., Lutianhua, Sichuan Meifeng, and Batian Co., Ltd. From 2022 to 2023, the company's biofuels were mainly applied in the European market, and in 2024, exports will gradually shift to regions such as Singapore and Switzerland.

As of the end of 2024, the company has a biodiesel production capacity of 105,000 tons, ranking sixth in China's biodiesel industry. FENGBEI BIOTECH stated that compared to comparable companies in the industry, such as Zhuoyue New Energy, Jiaao Enpro, and Longhai Biotech, the company's net profit attributable to the parent company after deducting non-recurring gains and losses in 2024 is less than that of Zhuoyue New Energy but greater than that of Jiaao Enpro and Longhai Biotech.

In terms of finance, in 2022, 2023, and 2024, the company achieved operating revenues of approximately 1.709 billion yuan, 1.728 billion yuan, and 1.948 billion yuan, respectively; during the same period, net profits were approximately 133 million yuan, 130 million yuan, and 124 million yuan, respectively. FENGBEI BIOTECH stated that from 2022 to 2023, the cash flow from operating activities was good, while the net cash flow from operating activities in 2024 decreased, mainly due to the growth in the balance of operating receivables.

### Related Stocks

- [603334.CN](https://longbridge.com/en/quote/603334.CN.md)

## Related News & Research

- [Xiaomi EV reportedly taps new battery suppliers for second brand to target EREV market](https://longbridge.com/en/news/286843996.md)
- [Pop star Wang Leehom swaps Denza endorsement fee for BYD stock](https://longbridge.com/en/news/286844734.md)
- [Goldman Sachs set to be named lead left underwriter for SpaceX IPO, source says](https://longbridge.com/en/news/286975906.md)
- [Market Chatter: Intel Urges PC Makers to Adopt Advanced CPUs Amid Supply Crunch](https://longbridge.com/en/news/286955059.md)
- [EXCLUSIVE: Google's AI Monetization Strategy May Be Leaving Rivals Behind, Says Direxion](https://longbridge.com/en/news/286919559.md)